Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Akums invested Rs. 272 crore in capital expenditure during FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
Investment demonstrates confidence in America’s commitment to science and innovation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated